{
    "root": "31352593-a65e-3b4e-e063-6294a90a49f9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Paliperidone",
    "value": "20250325",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "FUMARIC ACID",
            "code": "88XHZ13131"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:2)",
            "code": "5KY68S2577"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 100000",
            "code": "V46Y6OJ5QB"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "PALIPERIDONE",
            "code": "838F01T721"
        }
    ],
    "indications": "Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for Treatment of schizophrenia (1.1) Adults: Efficacy was established in three 6-week trials and one maintenance trial. (14.1) Adolescents (ages 12 to 17): Efficacy was established in one 6-week trial. (14.1) Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. (1.2) Efficacy was established in two 6-week trials in adult patients. (14.2)",
    "contraindications": "Initial Dose Recommended Dose Maximum Dose Schizophrenia - adults (2.1) 6 mg/day 3 to 12 mg/day 12 mg/day Schizophrenia-adolescents (2.1) Weight < 51 kg 3 mg/day 3 to 6 mg/day 6 mg/day Weight ≥ 51 kg 3 mg/day 3 to 12 mg/day 12 mg/day Schizoaffective disorder - adults (2.2) 6 mg/day 3 to 12 mg/day 12 mg/day Tablet should be swallowed whole and should not be chewed, divided, or crushed. (2.3)",
    "warningsAndPrecautions": "Paliperidone extended-release tablets,\n \n  1.5 mg, are supplied as brown, round, biconvex tablets, debossed “AN” over “80” on one side and plain on the other side. \n    They are available as follows:\n\n \n                  Bottles of 30:             NDC 65162-280-03 \n    Bottles of 90:             NDC 65162-280-09\n \n                  Paliperidone extended-release tablets,\n \n  3 mg, are supplied as white, round, biconvex tablets, debossed “AN” over “81” on one side and plain on the other side. \n    They are available as follows:\n\n \n                  Bottles of 30:             NDC 65162-281-03 \n    Bottles of 90:             NDC 65162-281-09\n \n                  Paliperidone extended-release tablets,\n \n  6 mg, are supplied as light beige, round, biconvex tablets, debossed “AN” over “82” on one side and plain on the other side. \n    They are available as follows:\n\n \n                  Bottles of 30:              NDC 65162-282-03 \n    Bottles of 90:              NDC 65162-282-09\n \n                  Paliperidone extended-release tablets,\n \n  9 mg, are supplied as pink, round, biconvex tablets, debossed “AN” over “83” on one side and plain on the other side. \n    They are available as follows:\n\n \n                  Bottles of 30:             NDC 65162-283-03 \n    Bottles of 90:             NDC 65162-283-09\n \n                  \n                     Storage and Handling\n                  \n                  Store at 20° to 25ºC (68° to 77ºF); excursions permitted between 15° to 30ºC (59° to 86ºF) [see USP Controlled Room Temperature]. Protect from moisture.\n                  Keep out of reach of children.",
    "adverseReactions": "Paliperidone extended-release tablets are contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone extended-release tablet formulation. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. Paliperidone is a metabolite of risperidone."
}